CARISMA THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 USD | -1.84% |
|
-2.44% | -45.39% |
| May. 02 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
| Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
Financials (USD)
| Sales 2024 * | 16.93M | Sales 2025 * | 13.83M | Capitalization | 66.47M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M | Net income 2025 * | -69M | EV / Sales 2024 * | 3.93 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.81 x |
| P/E ratio 2024 * |
-1.24
x | P/E ratio 2025 * |
-1.2
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.84% | ||
| 1 week | -2.44% | ||
| Current month | -1.84% | ||
| 1 month | -20.40% | ||
| 3 months | -25.23% | ||
| 6 months | -46.84% | ||
| Current year | -45.39% |
1 week
1.53
1.71
1 month
1.532.05
Current year
1.533.06
1 year
1.539.77
3 years
1.539.77
5 years
1.539.77
10 years
1.539.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 1.6 | -1.84% | 164,408 |
| 24-05-01 | 1.63 | 0.00% | 100,687 |
| 24-04-30 | 1.63 | -2.40% | 91,241 |
| 24-04-29 | 1.67 | +1.83% | 118,071 |
| 24-04-26 | 1.64 | 0.00% | 54,732 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.6
USD
Average target price
8.4
USD
Spread / Average Target
+425.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.39% | 66.47M | |
| -1.65% | 103B | |
| +6.75% | 101B | |
| +6.96% | 23.07B | |
| -12.60% | 22.23B | |
| -5.10% | 18.05B | |
| -39.98% | 17.18B | |
| -10.17% | 16.94B | |
| +6.12% | 14.07B | |
| +35.47% | 12.35B |
- Stock Market
- Equities
- CARM Stock
